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 Gout is a disease of recurrent, painful inflammatory episodes. While it is rarely life 
threatening, it can lead to disability after repeated attacks and resulting joint damage, therefore 
adequate control of acute inflammatory episodes and chronic hyperuricemia in the patient with 
gout is imperative. Patient M presented to the primary care clinic with a classic case of podagra. 
He, much like the other approximately 4% of the population that presents to their primary care 
provider with gout each year in the United States, had multiple secondary risk factors and 
comorbidities seen in the development of gout (Shmerling, 2012).  
Comorbidities are frequently seen in the patient with gout, and the American Academy of 
Rheumatology recommends screening for comorbidities this patient population (Khanna et al., 
2012). Patient M had a history of type 2 diabetes, hypertension, dyslipidemia, nephrolithiasis, 
obesity, recent alcohol use, high intake of purine rich foods, and thiazide diuretic use. These are 
all risk factors or comorbidities seen in patients with gout. At his office visit, his creatinine and 
glomerular filtration rate (GFR) were within normal limits; however, his multiple co-morbidities 
place him at a higher risk for chronic kidney disease, which could potentially complicate his 
treatment options in the future. Dalbeth, Merriman, and Stamp (2016) cited that 71% of patients 
with gout also have chronic kidney disease of stage 2 or greater. Also, hyperuricemia itself has 
been documented in epidemiological studies to be associated with the onset of new chronic 
kidney disease (Abdellatif & Elkhalili, 2014).  
The current cornerstone of gout therapy is multi-faceted. In addition to lifestyle 
modification, anti-inflammatory treatment during the acute periods of inflammation with low 
dose colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), or corticosteroids is 
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recommended. NSAIDs are often contraindicated in patients with any degree of chronic kidney 
disease due to risk of acute kidney injury. NSAID use also puts patients at risk of possible 
gastrointestinal complications. Colchicine has significantly reduced clearance in patients with 
chronic kidney disease and is associated with multiple serious drug-drug interactions, including 
simvastatin, and CYP3A4 and P-glycoprotein inhibitors (Abdellatif & Elkhalili, 2014; Stamp, 
2014). Anti-inflammatory agents are recommended prophylactically for at least 6 months 
following initiation of urate-lowering agents, therefore the provider must carefully select an 
agent that the patient with impaired renal function will tolerate (Khanna et al., 2012).  
In addition to treatment in acute flares of gout, urate-lowering therapies are utilized for 
treatment in patients with two or more episodes of gouty arthritis per year and chronic 
hyperuricemia (Dalbeth et al., 2016). Uric acid kidney stones and the diagnosis of chronic kidney 
disease of stage 2 or greater is considered an indication for treatment with urate-lowering therapy 
by the American College of Rheumatology guidelines (Khanna et al., 2012). While Patient M 
had a history of nephrolithiasis, the type of stone was unknown. Urate-lowering therapies include 
the use of allopurinol and febuxostat, which are both classified as xanthine oxidase inhibitors, 
probenecid, which promotes normalizing of serum urate through urinary excretion, and 
uricolytics, such as pegloticase (Dalbeth et al., 2016; Shmerling, 2012).  
Urate-lowering therapy for the treatment of gout requires dose adjustment or 
consideration of use in the patient with chronic kidney disease. For example, Stamp, et al. 
(2012), noted that in the patient with renal impairment, doses of allopurinol greater than or equal 
to 300 milligrams per day is associated with allopurinol hypersensitivity syndrome (AHS). The 
American College of Rheumatology guidelines for gout management suggest beginning urate-
lowering therapy with lower doses of allopurinol, however the lower doses are often ineffective 
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at reaching serum urate goals. And, probenecid is contraindicated in patients with a creatinine 
clearance of <50ml/min (Khanna et al., 2012).  
With gout and chronic kidney disease being of such common prevalence in the United 
States, the fact that one condition exacerbates the other, and the need for modification of typical 
medication management of gout in the patient with chronic kidney disease, the purpose of this 
report is to review literature that discusses changes to the medication regimen for treating 
patients in primary care with acute gouty arthritis and chronic kidney disease.  
Case Report 
 Patient M, a 46 year-old Caucasian male with a history significant for obesity, 
hypertension, type 2 diabetes mellitus, hypercholesterolemia, and nephrolithiasis presented to the 
primary care clinic with complaints of pain and swelling in his right great toe. His discomfort 
had started acutely the morning of his presentation. He described it as a continuous, throbbing-
type pain. It did not radiate. He rated his pain a 6 on a 0-10 scale. He denied any over-the-
counter attempts at managing his pain at home. He denied injury to the area. He also denied 
fever, chills, chest pain, shortness of breath, claudication, and history of neuropathy and ingrown 
toenail. As a diabetic, he did not report seeing podiatry routinely; however, he stated that his last 
visit to his primary care provider was two months ago, and since that time there has been no 
change in his condition, except his great toe pain. He checks his blood sugar occasionally at 
home and his results have been in the low 100s. He stated that yesterday he partook in a game of 
curling with a group of friends and after this he consumed approximately three alcoholic 
beverages in the form of beer. He also reports frequent consumption of sardines. His current 
medications included metformin, lisinopril, hydrochlorothiazide, aspirin, and a statin.  
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 He was afebrile and his other vital signs were within normal limits. He was considered 
obese, with a body mass index (BMI) of 29. His physical exam revealed a 46 year-old Caucasian 
male sitting upright in the exam room. He was in no acute distress. He was alert and oriented to 
person, place, and time. He was felt to be a reliable historian. His lungs were clear throughout all 
fields and his heart tones were regular without skips, gallops, or rubs. Monofilament testing was 
within normal limits to bilateral feet. There were 2+ pedal pulses and 2+ posterior tibial pulses 
noted bilaterally. On inspection, his right first metatarsophalangeal joint was erythematous, 
warm, and slightly edematous. Tenderness was reported on light palpation. In general, skin to 
feet and ankles was intact and without laceration or abrasion. Toenails were in good condition. 
 After history taking and physical exam, the likely diagnosis was acute gouty arthritis. 
Differentials included soft tissue cellulitis, septic arthritis, and rheumatoid arthritis. Laboratory 
evaluation including basic metabolic panel, complete blood count, erythrocyte sedimentation 
rate, C-reactive protein, rheumatoid factor, and uric acid was obtained and revealed elevation of 
his uric acid at 10.9. Because of this, joint aspiration of the right first metatarsophalangeal joint 
was carried out, which revealed monosodium urate crystals, confirming the diagnosis of acute 
gouty arthritis. The patient was treated with oral non-steroidal anti-inflammatory agent, 
Naproxen.  Dietary counseling was provided regarding reducing intake of high purine foods, 
including alcohol and sardines. Non-weight bearing to right foot and rest until resolution of acute 
attack. The patient was instructed to return to the clinic in one week for monitoring of his acute 
gouty arthritis and blood pressure management. This was his first episode of gout, therefore 
urate-lowering therapy was not considered.  
 Patient M presented to the clinic with a classic case of acute gouty arthritis. He had 
multiple risk factors for acquiring this condition including: male gender, hypertension, history of 
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kidney stones, intake of purine rich foods including sardines and alcohol, increased weight, and 
use of the medication hydrochlorothiazide for blood pressure management. The management of 
his condition was straightforward, as his laboratory evaluation was without abnormality with the 
exception of his uric acid. A potential confounder in the management of his gouty arthritis if it 
recurs in the future could possibly include chronic kidney disease, a condition for which he 
already possesses risk factors for at the age of 46; including hyperuricemia, hypertension, and 
diabetes. Multiple considerations are taken when prescribing treatment for gout in the patient 
with chronic kidney disease. As stated earlier, the pathophysiology of one disease process 
contributes to the development of the other.        
Literature Review 
 While there are multiple medications available for both the acute inflammatory periods 
and chronic urate-lowering therapy in gout, providers must be aware of potential complications 
of treatments and safe alternatives for patients with chronic kidney disease. This literature review 
will address treatment options in the acute inflammatory period and chronic urate-lowering 
therapy in the patient with chronic kidney disease in primary care. Presently, there are new 
inhibitors of the pro-inflammatory cytokine interleukin-1B that have been studied in acute gouty 
arthritis; however, they were excluded from this review as they present cost barriers and are not 
commonly utilized in the primary care setting (Abdellatif & Elkhalili, 2014).   
Acute Inflammatory Management in Chronic Kidney Disease 
 The most effective management strategy in the acute inflammatory period of gouty 
arthritis is to begin anti-inflammatory treatment at the earliest sign of an acute flare (Gaffo & 
Saag, 2008). NSAIDs, such as naproxen and indomethacin, and colchicine are generally 
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contraindicated in chronic kidney disease. While corticosteroids can have detrimental adverse 
effects in long-term use, in the primary care setting, corticosteroids may be the preferred 
treatment option for acute gouty arthritis in the patient with chronic kidney disease.  
Rainer et al. (2016) performed a double-blind, randomized trial comparing oral 
prednisolone to indomethacin and their effectiveness in the treatment of acute gout. Each of the 
medications was used in combination with acetaminophen. In their study, patients, mostly male 
with a mean age of 65 years, who presented to the emergency department in Hong Kong with 
acute gouty arthritis were randomized to receive either indomethacin 50mg three times daily for 
two days and then 25 mg three times daily for three days, or oral prednisolone 30 mg per day for 
five days (Rainer et al., 2016). Renal insufficiency was reported by 35% of the patients (Rainer 
et al., 2016). They evaluated the effectiveness of each medication by monitoring joint pain at rest 
and with activity two hours after receiving the medication, and at day fourteen following 
treatment. Adverse events (dizziness, sleepiness, nausea, vomiting, abdominal pain, indigestion, 
rash, dry mouth, and any other symptom the patient reported) were also monitored. Fewer 
patients in the prednisolone group had adverse events in the first two hours. The groups did not 
differ in adverse events at day fourteen, and the groups did not differ for change in pain at day 14 
(Rainer et al., 2016). There were no serious adverse events in either group. This showed that 
prednisolone was as effective as indomethacin in these patients. Limitations included the 
comparison of just indomethacin as an NSAID compared to the prednisolone, and the fact that 
diagnosis was based on clinical assessment, not necessarily on joint aspirate. Due to the fact that 
both medications were used in combination with acetaminophen as needed, one cannot conclude 
that prednisolone alone was efficacious in the management of acute gouty arthritis.  
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While Rainer et al. used indomethacin in comparison to prednisolone, Janssens, Janssen, 
van de Lisdonk, van Riel, and van Weel (2008), performed a double-blind, randomized 
equivalence trial of naproxen versus prednisolone in the treatment of gouty arthritis in the 
primary care clinic. Their study included 59 patients randomized to receive prednisolone 35 mg 
once daily for five days, and 59 patients randomized to receive naproxen 500mg twice daily for 
five days (Janssens et al., 2008). 89% of the subjects were male and their average age was 57 
years old. Some eligible patients in this trial were excluded due to possible risks, such as 
gastrointestinal bleeding and pre-existing renal disease, if treated with NSAIDs. They compared 
pain ratings of each group after 90 hours of treatment and found equivalent reduction in pain 
scores between the two groups (Janssens et al., 2008). The adverse effects (gastric or abdominal 
pain, itch or dizziness, dyspnea or palpitations, or other adverse effects) described by 66% of the 
patients taking prednisolone and 63% of the patients taking Naproxen had all resolved by three 
weeks after the study (Janssens et al., 2008). Although this study was much smaller compared to 
the comparison of indomethacin and prednisolone, the subjects included here had confirmed 
monosodium urate crystals on joint aspiration. It is possible that Rainer et al. were treating 
patients that were unaffected by gout and were suffering from another condition, such as reactive 
arthritis, rheumatoid arthritis, or pseudogout. This a potential confounder in their findings.  
Another study comparing the analgesic efficacy, anti-inflammatory effect, and 
tolerability of the corticosteroid, prednisolone, to indomethacin, and etoricoxib, a selective 
cyclooxygenase (COX)-2 inhibitor, in acute gout was completed by Xu, Liu, Guan, and Xue in 
2016. This study was completed in China, was open label, and was randomized. Xu, et al. 
(2016), analyzed a total of 113 patients, mostly men with a mean age of 44 years old, diagnosed 
with acute gouty arthritis based on clinical criteria. The patients were given either 35 mg of 
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prednisolone daily, etoricoxib 120mg daily, or indomethacin 50 mg three times daily. Adverse 
effects over four days were recorded. Adverse effects included gastric or abdominal pain, 
dizziness, edema, fatigue or drowsiness, and dry mouth. The three medications were similar in 
their ability to reduce pain, while prednisolone may have been slightly more effective in 
reducing swelling (Xu, et al., 2016). Indomethacin was associated with more adverse effects 
compared to etoricoxib, but none of the adverse effects were serious (Xu, et al., 2016).  
Limitations of this study included its small sample sizes and lack of absolute confirmatory 
aspirate revealing monosodium urate crystals. Compared to Rainer, et al. (2016), this study did 
not utilize prednisolone in combination with acetaminophen, perhaps leading one to be able to 
draw the conclusion that prednisolone alone is effective in the management of acute gouty 
arthritis. 
Wechalekar, et al. (2014) performed a systematic review comparing acute gout 
management therapies and their effectiveness of pain management and adverse events. This 
review included a Cochrane Review. Five studies looked at glucocorticoids, 21 studies looked at 
NSAIDs, two studies reviewed colchicine, and one study reviewed the interleukin inhibitor, 
canakinumab (Wechalekar, et al., 2014). Through their review, Wechalekar, et al. (2014) were 
able to conclude that systemic glucocorticoids appeared safer than NSAIDs and colchicine, and 
that systemic glucocorticoids were just as effective at management. Systematic reviews are 
generally regarded as providing high quality evidence. While parts of this systematic review are 
not applicable to this literature review, this provides evidence again for the safety and efficacy of 
short-term glucocorticoid use in acute gouty arthritis.  
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Management of Chronic Hyperuricemia in Chronic Kidney Disease 
Beyond the acute inflammatory phase of gout, many patients require urate-lowering 
prophylactic therapy to prevent recurrent attacks and resulting disability from joint damage. 
Allopurinol is a frequently used urate-lowering therapy that in the past, was dosed based on the 
Hande criteria, utilizing the patient’s creatinine clearance (Stamp, et al., 2011). Stamp, et al. 
(2011) enrolled 90 patients who had been on allopurinol for at least one month, and 
incrementally increased their allopurinol dose by 50-100mg each month if their serum urate 
concentration was greater than or equal to 6mg/dl, until their serum urate concentration was less 
than 6mg/dl. 87.9% of the patients enrolled were male and their average age was 58.7 years old 
(Stamp, et al., 2011). The patients had multiple co-morbidities. 45 of the patients enrolled had 
serum urate concentrations greater than or equal to 6mg/dl while on the allopurinol dose that was 
based on their creatinine clearance, and therefore underwent incremental dose adjustments of 
their allopurinol (Stamp, et al., 2011). After 12 months of dose increases, the mean dose of 
allopurinol was 359.7 mg/day, and the patients were able to achieve a serum urate level less than 
6 mg/dl without adverse reaction (Stamp, et al., 2011). This study shows that when using 
allopurinol in patients with renal impairment, one can safely increase allopurinol dosing with 
careful monitoring in order to achieve serum urate levels less than 6mg/dl. The likely benefit of 
having serum urate levels at below saturation far outweigh the risk of developing the AHS in the 
patient with renal impairment. This study was small, so larger studies would be indicated, but its 
importance is great when considering the cost of allopurinol versus other urate-lowering 
therapies.  
Thurston, Phillips, and Bourg (2013) also had interest in studying the safety and efficacy 
of allopurinol in the patient with chronic kidney disease. They performed a literature review to 
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determine if a renally-dosed regimen of allopurinol had been consistently studied in the 
literature. They found that randomized-controlled trials of the use of allopurinol in gout in 
patients with chronic kidney disease is lacking, and that the studies that have been completed 
have not demonstrated consistency regarding the safety and efficacy of allopurinol (Thurston et 
al., 2013). The studies reviewed also lacked consistency in their definition of chronic kidney 
disease (Thurston et al., 2013). From their review they drew the conclusion that definitive 
research is needed, and that providers should be aware of the need to educate patients with 
chronic kidney disease who are placed on allopurinol about the possibility of and signs and 
symptoms of AHS (Thurston, et al., 2013).  
Research of allopurinol in gout management in the setting of chronic kidney disease has 
not been definitive. Febuxostat, a non-purine analogue xanthine-oxidase inhibitor, which is 
metabolized by both the kidneys and the liver, has been studied for its ability to lower urate 
levels effectively in patients with renal impairment (Tsuruta et al., 2014). Tsuruta et al. (2014), 
examined a cohort of 73 hyperuricemic patients who had an estimated glomerular filtration rate 
(eGFR) below 45ml/min and were already on urate-lowering therapy with allopurinol for 
changes in urate levels and eGFR with therapy of febuxostat versus continued allopurinol 
therapy after one year. 51 patients were prescribed febuxostat in place of allopurinol, and 22 
patients were continued on allopurinol. After one year of treatment, febuxostat patients had 
lower uric acid levels, while the allopurinol cohort’s uric acid levels actually increased.  
While this study looked promising for use of febuxostat, there were significant 
limitations. The sample of patients studied was small. The dosing of febuxostat was not 
standardized, as patients were treated with both 10 mg and 20 mg doses. Also, the allopurinol 
group was likely under treated, as there was no up titration of allopurinol based on patient 
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tolerance. The allopurinol cohort was treated with either 50 mg, 100 mg, or 200 mg throughout 
the study. The patients in this study had an eGFR <45 ml/min, so one may hypothesize that the 
10 mg or 20 mg dose of febuxostat would be safe to use in patients with better kidney function. 
Something that also must be considered is the cost effectiveness of feboxostat versus allopurinol.  
Saag et al. (2016) also examined febuoxstat in renal impairment. They examined serum 
urate reduction and renal function by performing a randomized, double-blind, placebo-controlled 
study comparing 96 patients with gout, serum uric acid levels greater than or equal to 7 mg/dl, 
and moderate to severe renal impairment (eGFR of 15-50 ml/minute) (Saag et al., 2016). They 
randomized their patients at a 1:1:1 to receive 30mg febuxostat twice daily, 40/80 mg febuxostat 
once daily, or placebo (Saag et al., 2016). A total of 57 patients completed the study and the 
highest percentage of patients that withdrew from the study due to an adverse event were from 
the placebo group (Saag et al., 2016). After 12 months, serum creatinine and eGFR were not 
significantly changed in all groups; however, in the febuxostat groups, there was significantly 
better reduction in serum urate levels to a serum urate level of less than 6 mg/dl. A possible 
confounder in this study was the fact that there was a heavy proportion (53%) of patients in the 
placebo group with severe renal impairment.  
Sakai et al. (2014) compared febuxostat and allopurinol in the Japanese population with 
eGFR less than 60ml/minute, who had failed to achieve serum uric acid concentration of less 
than 6 while on allopurinol, and who had been on febuxostat for six months or longer. They used 
a retrospective observational exploratory study (Sakai et al., 2014). Sakai et al. (2014) reviewed 
medical records of 60 patients and compared serum uric acid levels 6 months before and 6 
months after switching to febuxostat. The average dose of allopurinol prior to febuxostat use was 
71.3 mg/day, and febuxostat was dosed between 10-40 mg (Sakai et al., 2014). After 6 months of 
Running head: GOUT MANAGEMENT IN CHRONIC KIDNEY DISEASE  14 
 
febuxostat treatment, mean serum uric acid concentrations decreased from 8.4 mg/dl to 6.2 
mg/dl, and there was an increase in eGFR with febuxostat treatment (Sakai et al., 2014).  In their 
review, Sakai et al. (2014) repeatedly mentioned that prior to the placement on febuxostat, the 
patients on allopurinol had a, “slow but steady decline in eGFR” in the 6 months prior to the 
switch. While this may be true, one must question the aggressiveness and up-titration of 
allopurinol dosing (based on patient tolerance) in order to reduce serum urate in the patient 
population.  This sample was again, small. The retrospective observational study lacks strength 
of quality of evidence, so further study in a larger patient population is needed.  
The final study reviewed was completed by Schumacher et al. (2008) and was a 
randomized, double-blind trial that compared urate-lowering efficacy of febuxostat, allopurinol, 
and placebo in 1,072 subjects with hyperuricemia (serum urate greater than 8) and gout. The 
study included a small subset of patients with impaired renal function, with serum creatinine 
ranging from greater than 1.5 mg/dl to less than or equal to 2 mg/dl. In the group with impaired 
renal function, 25 subjects were treated with varying doses of febuxostat (80mg, 120mg, or 
240mg daily) and 10 subjects were treated with allopurinol 100mg daily (Schumacher et al., 
2008). The study took place over 28 weeks and the effectiveness of each treatment was based on 
a monthly serum urate level during each of the last three months of the trial (Schumacher et al., 
2008). 12 of the 25 subjects with impaired renal function treated with febuxostat reached the goal 
serum urate level of less than 6, while 0 of the 10 subjects treated with 100mg of allopurinol 
reached the goal serum urate level (Schumacher et al., 2008). While this study was a 
randomized-controlled trial, it contained a very small subset of patients that had impaired renal 
function. And, like the other studies comparing allopurinol effectiveness versus febuxostat 
effectiveness in the patient with chronic kidney disease, the allopurinol was likely under dosed. 
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There was no attempt at up titration, which places allopurinol at somewhat of an unfair 
advantage.  
Learning Points 
 Much thought, time, effort, and study was placed into this work, and with this comes an 
expansion of knowledge about the general condition of gout, the risk factors for the condition, 
and different options for treatment. Currently there are multiple studies in the literature about 
hyperuricemia, gout, and the relationship to chronic diseases, specifically chronic kidney disease 
and cardiovascular disease. It seems that uric acid may be on the horizon of being a laboratory 
value that is routinely monitored in primary care. As gout and chronic kidney disease are 
frequently encountered in primary care, it seemed valuable to evaluate their management.  
• The management of gout is multi-faceted, and this concept was applied in Patient M’s 
care. He received education about lifestyle management. Medication was prescribed for 
the acute inflammatory episode, and consideration for future treatment options was given. 
• Short-term, or “burst” corticosteroid therapy, specifically with prednisolone, as reviewed 
above, appears safe for use in the patient with acute gouty arthritis and chronic kidney 
disease. Corticosteroid use while initiating urate-lowering therapy could also be used in 
the patient with renal impairment (recommended to continue anti-inflammatory treatment 
for 6 months).  
• Urate-lowering therapy is considered in the patient with stage 2-5 chronic kidney disease 
and in patients with hyperuricemia and two or more episodes of acute gouty arthritis per 
year. This literature review focused on the use of allopurinol and febuxostat as options 
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for patients with chronic kidney disease. The provider and patient must be willing to 
work together with up-titration to achieve serum urate goals of 6 or less.  
• An up titration of allopurinol could first be considered if cost of care is an issue before 
moving to febuxostat for urate-lowering therapy.  
• Febuxostat has been proven effective for serum urate-lowering in the patient with chronic 
kidney disease. Some studies have included patients with severe renal impairment, which 
likely would be addressed in nephrology rather than primary care, but is still useful for 
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